Skip to main content
Passa alla visualizzazione normale.


Osteonecrosis detected by whole body magnetic resonance in patients with Hodgkin Lymphoma treated by BEACOPP

  • Authors: Albano, D.; Patti, C.; la Grutta, L.; Grassedonio, E.; Mulè, A.; Brancatelli, G.; Lagalla, R.; Midiri, M.; Galia, M.
  • Publication year: 2017
  • Type: Articolo in rivista (Articolo in rivista)
  • OA Link:


Objectives: The purpose of our retrospective review of prospectively acquired Whole Body Magnetic Resonance (WB-MRI) scans was to assess the incidence of osteonecrosis in patients who received different chemotherapies. Methods: We evaluated the WB-MRI scans performed on 42 patients with Hodgkin Lymphoma treated by three chemotherapy regimens (6ABVD, 2ABVD + 4BEACOPP, 2ABVD + 8BEACOPP), excluding patients with the main risk factors for osteonecrosis. Results: Six out of seven patients (86 %) who received eight BEACOPP and one out of five patients (20 %) treated by four BEACOPP presented osteonecrosis, with a statistically significant difference of frequency between the two groups of patients (p < 0.05); no injury has been reported in patients treated by only ABVD. Among a total of 48 osteonecrotic lesions observed, 48 % were detected in the knee; multifocal osteonecrosis were detected in six out of seven patients (86 %). Conclusions: The development of osteonecrosis is strictly related to the chemotherapy protocol adopted and the number of cycles received, with a strong correlation between the dose of corticosteroids included in the BEACOPP scheme and this complication. WB-MRI can be considered as a helpful tool that allows detecting earlier osteonecrotic lesions in patients treated with corticosteroids. Key Points: • Osteonecrosis is a possible complication of patients with Lymphoma treated by chemotherapy.• Osteonecrosis is related to the corticosteroids included within the BEACOPP protocol.• WB-MRI allows detecting osteonecrotic lesions in patients treated with corticosteroids.